Hanmi Pharm and GC Pharma plan to jointly develop new global innovative drugs for rare diseases.
Hanmi Pharm and GC Pharma have signed a contract to jointly develop a next-generation innovative drug to treat LSD (Lysosomal Storage Diseases), a rare hereditary disease.
They signed a memorandum of understanding (MOU) on R&D cooperation in February this year.
"LSD" is a rare disease in which "lysosome," a cell organ that removes damaged cell debris or unnecessary materials, continues to accumulate in the body for unknown reasons, causing serious metabolic diseases and leading to death.
At present, LSD patients are mainly treated with ERT (Enzyme Replacement Therapy), a method of intravenous injection of enzymes developed by gene recombination technology.
Kwon Se-chang, CEO of Hanmi Pharm, said, "Hanmi Pharm and GC Pharma have been working together since February. We will do our best to maximize the capabilities of both companies so that differentiated treatments can be developed."
Meanwhile, Huh Eun-chul, CEO of GC Pharma, said, "We hope that bilateral cooperation will make meaningful changes in patients' lives. We will continue to cooperate in various forms in the future, focusing on areas where unfulfilled medical demand is high."